Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Tri-modal management of primary small cell carcinoma of the pancreas (SCCP): a rare neuroendocrine carcinoma (NEC)

Fig. 4

A PET scan prior to treatment (4/23/2019) showing moderate FDG avidity in the pancreatic mass, with an SUV max reaching 7.5 g/mL (Arrow). There is some uptake in adjacent nodes. B PET scan after 3 cycles (6/6/2019) of cisplatin/etoposide showing decrease in the PET activity involving the pancreatic mass with a maximum SUV value of 3.2 versus 7.6 on prior examination (Arrow). The adjacent peripancreatic PET avid lymph node also demonstrates decreased activity. C PET scan after 6 cycles (9/20/2019) of cisplatin/etoposide showing resolution of mild residual uptake in the peripancreatic foci (Arrow). D Post-operative PET Gallium without definite increased radiotracer uptake in the surgical bed to suggest DOTATATE-avid residual disease. Low level activity along the pancreatic remnant is nonspecific

Back to article page